Cryoport, Inc. (CYRX) — SEC Filings
Cryoport, Inc. (CYRX) — 36 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 13 8-K, 9 SC 13G/A, 6 10-Q.
View Cryoport, Inc. on SEC EDGAR
Overview
Cryoport, Inc. (CYRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Cryoport, Inc. (CYRX) reported a significant turnaround in net income for the nine months ended September 30, 2025, reaching $89.945 million, a substantial improvement from a net loss of $96.079 million in the prior year. This positive shift was primarily driven by a $115.393 million income from dis
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 1 bullish, 35 neutral. The dominant filing sentiment for Cryoport, Inc. is neutral.
Filing Type Overview
Cryoport, Inc. (CYRX) has filed 6 10-Q, 13 8-K, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 4 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of CYRX's 24 recent filings, 0 were flagged as high-risk, 8 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $130.727M |
| Net Income | $89.945M |
| Cash Position | $255.811M |
Industry Context
Cryoport operates in the specialized logistics sector for life sciences, a rapidly growing market driven by advancements in cell and gene therapies, biopharmaceuticals, and regenerative medicine. The industry demands stringent temperature control, regulatory compliance, and reliable delivery of high-value, sensitive biological materials. Key trends include increasing outsourcing of logistics by biotech firms and a growing need for global cold chain solutions.
Top Tags
financial-reporting (7) · 8-k (5) · 10-Q (5) · financials (4) · sec-filing (4) · corporate-governance (3) · quarterly-report (3) · Cryoport (3) · Life Sciences Logistics (2) · 10-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $89.945M | Nine months ended Sept 30, 2025, a swing from -$96.079M loss in 2024 |
| Total Revenue | $130.727M | Nine months ended Sept 30, 2025, up 13.37% from $115.317M in 2024 |
| Cash and Cash Equivalents | $255.811M | As of Sept 30, 2025, a significant increase from $34.137M at Dec 31, 2024 |
| Income from Discontinued Operations | $115.393M | Nine months ended Sept 30, 2025, a key driver of net income |
| CRYOPDP Divestiture Price | $133.0M | Amount received from DHL for the sale of the CRYOPDP business |
| Net Loss | $6.943M | Three months ended Sept 30, 2025, indicating ongoing operational challenges despite overall nine-month profit |
| Life Sciences Services Revenue Growth | 18.04% | Increase to $71.492M for nine months ended Sept 30, 2025 |
| Life Sciences Products Revenue Growth | 8.19% | Increase to $59.235M for nine months ended Sept 30, 2025 |
| End of reporting period | 2025-06-30 | The quarter for which the 10-Q was filed. |
| Filing date | 2025-08-12 | Date the 10-Q was officially filed with the SEC. |
| Central Index Key (CIK) | 0001124524 | Unique identifier for Cryoport, Inc. with the SEC. |
| Public Document Count | 104 | Number of documents included in the filing. |
| Reporting Period End Date | 20250331 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Filing Date | 20250508 | The date the 10-Q was officially submitted to the SEC. |
| Period of Report | 20250606 | The period this proxy statement pertains to. |
Forward-Looking Statements
- {"claim":"Morgan Stanley will maintain its passive stake in Cryoport, Inc. for the foreseeable future.","entity":"Morgan Stanley","targetDate":"Q4 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cryoport, Inc. (CYRX)?
Cryoport, Inc. has 36 recent SEC filings from Jan 2024 to Nov 2025, including 13 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CYRX filings?
Across 36 filings, the sentiment breakdown is: 1 bullish, 35 neutral. The dominant sentiment is neutral.
Where can I find Cryoport, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cryoport, Inc. (CYRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cryoport, Inc.?
Key financial highlights from Cryoport, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CYRX?
The investment thesis for CYRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cryoport, Inc.?
Executive information for Cryoport, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Cryoport, Inc. stock?
Of CYRX's 24 assessed filings, 0 were flagged high-risk, 8 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Cryoport, Inc.?
Recent forward-looking statements from Cryoport, Inc. include guidance on {"claim":"Morgan Stanley will maintain its passive stake in Cryoport, Inc. for the foreseeable future.","entity":"Morgan.